File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Prevalence and Prognostic Importance of Massive Tricuspid Regurgitation in Patients Undergoing Tricuspid Annuloplasty With Concomitant Left-Sided Valve Surgery: A Study on Rheumatic Valvular Heart Disease

TitlePrevalence and Prognostic Importance of Massive Tricuspid Regurgitation in Patients Undergoing Tricuspid Annuloplasty With Concomitant Left-Sided Valve Surgery: A Study on Rheumatic Valvular Heart Disease
Authors
Keywordsadverse outcome
effective regurgitant orifice area (EROA)
left-sided valve disease
rheumatic valvular heart disease
tricuspid annuloplasty
tricuspid regurgitation (TR)
Issue Date2022
Citation
Frontiers in Cardiovascular Medicine, 2022, v. 9, article no. 686208 How to Cite?
AbstractBackground: The presence of tricuspid regurgitation (TR) is very common in patients with concomitant left-sided valve disease. Recent studies have advocated an additional grading of massive TR that is beyond severe. The present study sought to characterize the spectrum of TR in patients undergoing tricuspid annuloplasty (TA) and to evaluate the prognostic value of TR severity for post-operative outcome following TA. Methods: A total of 176 patients who underwent TA with combined left-sided valve surgery, secondary to rheumatic valvular heart disease, were prospectively evaluated. The severity of TR was quantified by effective regurgitant orifice area (EROA) using the proximal isovelocity surface area method. Patients were categorized as having non-massive TR (EROA < 0.6 cm2) or massive TR (EROA ≥ 0.6 cm2). Adverse outcome was defined as all-cause mortality or heart failure requiring hospital admission following TA. Results: A total of 55 (31%) patients were considered to have massive TR. Patients with massive TR had a greater right ventricular dimension but a smaller left ventricular dimension compared with those with non-massive TR. After a median follow-up of 39 months, 35 adverse events occurred. Cox-regression analysis showed that both continuous EROA and dichotomized EROA (massive vs. non-massive TR) were independently associated with adverse events even after multivariable adjustment. Further, Harrell C index demonstrated that the addition of massive TR provided better discrimination ability of a prediction model to known prognosticators following TA. Conclusions: Massive TR is common and up to 31% of study population had massive TR. Massive TR was associated with adverse outcome in patients undergoing TA. Classification of the severity of TR by quantitative measures and identification of massive TR in patients with concomitant left-sided valve disease are essential when considering the optimal timing of corrective surgery.
Persistent Identifierhttp://hdl.handle.net/10722/358062
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorChen, Yan-
dc.contributor.authorChan, Yap Hang-
dc.contributor.authorWu, Mei Zhen-
dc.contributor.authorYu, Yu Juan-
dc.contributor.authorLam, Yui Ming-
dc.contributor.authorSit, Ko Yung-
dc.contributor.authorChan, Daniel Tai Leung-
dc.contributor.authorHo, Cally Ka Lai-
dc.contributor.authorHo, Lai Ming-
dc.contributor.authorLau, Chu Pak-
dc.contributor.authorAu, Wing Kuk-
dc.contributor.authorTse, Hung Fat-
dc.contributor.authorYiu, Kai Hang-
dc.date.accessioned2025-07-23T03:00:53Z-
dc.date.available2025-07-23T03:00:53Z-
dc.date.issued2022-
dc.identifier.citationFrontiers in Cardiovascular Medicine, 2022, v. 9, article no. 686208-
dc.identifier.urihttp://hdl.handle.net/10722/358062-
dc.description.abstractBackground: The presence of tricuspid regurgitation (TR) is very common in patients with concomitant left-sided valve disease. Recent studies have advocated an additional grading of massive TR that is beyond severe. The present study sought to characterize the spectrum of TR in patients undergoing tricuspid annuloplasty (TA) and to evaluate the prognostic value of TR severity for post-operative outcome following TA. Methods: A total of 176 patients who underwent TA with combined left-sided valve surgery, secondary to rheumatic valvular heart disease, were prospectively evaluated. The severity of TR was quantified by effective regurgitant orifice area (EROA) using the proximal isovelocity surface area method. Patients were categorized as having non-massive TR (EROA < 0.6 cm<sup>2</sup>) or massive TR (EROA ≥ 0.6 cm<sup>2</sup>). Adverse outcome was defined as all-cause mortality or heart failure requiring hospital admission following TA. Results: A total of 55 (31%) patients were considered to have massive TR. Patients with massive TR had a greater right ventricular dimension but a smaller left ventricular dimension compared with those with non-massive TR. After a median follow-up of 39 months, 35 adverse events occurred. Cox-regression analysis showed that both continuous EROA and dichotomized EROA (massive vs. non-massive TR) were independently associated with adverse events even after multivariable adjustment. Further, Harrell C index demonstrated that the addition of massive TR provided better discrimination ability of a prediction model to known prognosticators following TA. Conclusions: Massive TR is common and up to 31% of study population had massive TR. Massive TR was associated with adverse outcome in patients undergoing TA. Classification of the severity of TR by quantitative measures and identification of massive TR in patients with concomitant left-sided valve disease are essential when considering the optimal timing of corrective surgery.-
dc.languageeng-
dc.relation.ispartofFrontiers in Cardiovascular Medicine-
dc.subjectadverse outcome-
dc.subjecteffective regurgitant orifice area (EROA)-
dc.subjectleft-sided valve disease-
dc.subjectrheumatic valvular heart disease-
dc.subjecttricuspid annuloplasty-
dc.subjecttricuspid regurgitation (TR)-
dc.titlePrevalence and Prognostic Importance of Massive Tricuspid Regurgitation in Patients Undergoing Tricuspid Annuloplasty With Concomitant Left-Sided Valve Surgery: A Study on Rheumatic Valvular Heart Disease-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.3389/fcvm.2022.686208-
dc.identifier.scopuseid_2-s2.0-85135924249-
dc.identifier.volume9-
dc.identifier.spagearticle no. 686208-
dc.identifier.epagearticle no. 686208-
dc.identifier.eissn2297-055X-
dc.identifier.isiWOS:000753484200001-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats